Interleukin 28 is a potential therapeutic target for sepsis

Clin Immunol. 2019 Aug:205:29-34. doi: 10.1016/j.clim.2019.05.012. Epub 2019 May 20.

Abstract

Identification of new therapeutic targets for the treatment of sepsis is imperative. We report here that cytokine IL-28 (IFN-λ) levels were elevated in clinical and experimental sepsis. Neutralization of IL-28 protected mice from lethal sepsis induced by cecal ligation and puncture (CLP), which was associated with improved bacterial clearance and enhanced neutrophil infiltration. Conversely, administration of recombinant IL-28 aggravated mortality, facilitated bacterial dissimilation and limited neutrophil recruitment, in the model of sepsis induced by CLP. This study defines IL-28 as a detrimental mediator during sepsis and identifies a potential therapeutic target for the immune therapy in sepsis.

Keywords: Immunity; Infection; Interleukin-28; Neutrophil; Sepsis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Animals
  • Antibodies, Neutralizing / pharmacology*
  • Cecum / surgery
  • Cytokines / antagonists & inhibitors*
  • Cytokines / pharmacology
  • Disease Models, Animal
  • Female
  • Humans
  • Interleukins / antagonists & inhibitors*
  • Interleukins / immunology*
  • Interleukins / pharmacology
  • Intestinal Perforation
  • Male
  • Mice
  • Middle Aged
  • Molecular Targeted Therapy
  • Mortality
  • Neutrophil Infiltration / drug effects*
  • Neutrophil Infiltration / immunology
  • Sepsis / immunology*

Substances

  • Antibodies, Neutralizing
  • Cytokines
  • interferon-lambda, human
  • IL28A protein, mouse
  • Interleukins
  • interferon-lambda protein, mouse